

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
3 January 2002 (03.01.2002)

PCT

(10) International Publication Number
WO 02/00197 A1

- (51) International Patent Classification⁷: **A61K 9/14, 47/26**
- (21) International Application Number: **PCT/GB01/02860**
- (22) International Filing Date: **27 June 2001 (27.06.2001)**
- (25) Filing Language: **English**
- (26) Publication Language: **English**
- (30) Priority Data:
00113608.4 27 June 2000 (27.06.2000) EP
0029263.1 30 November 2000 (30.11.2000) GB
PCT/GB01/01732 17 April 2001 (17.04.2001) GB
- (71) Applicant (*for all designated States except US*): **VECTURA LIMITED** [GB/GB]; University of Bath Campus, Claverton Down, Bath BA2 7AY (GB).
- (72) Inventors; and
- (75) Inventors/Applicants (*for US only*): **STANFORTH, John, Nicholas** [GB/GB]; High Trees, Bloomfield Road, Bath BA2 2ST (GB). **MORTON, David, Alexander, Voden** [GB/GB]; 2nd Floor Flat, Linsley House, Beechen Cliff Road, Bath BA2 4QR (GB). **MUSA, Rosella** [IT/IT]; Chiesi Farmaceutici SpA, Via Palermo 26/A, I-43100 Parma (IT).
- (74) Agents: **DENNESS, James, Edward et al.**; Abel & Imray, 20 Red Lion Street, London WC1R 4PQ (GB).
- (81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.
- (84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).
- Published:**
— *with international search report*
- For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*



WO 02/00197 A1

(54) Title: **METHOD OF MAKING PARTICLES FOR USE IN A PHARMACEUTICAL COMPOSITION**

(57) Abstract: A method for making composite excipient particles for use in a pharmaceutical composition comprises a milling step in which particles of an excipient material are milled in the presence of an additive material. The product particles are of small size and the milling requires relatively low input of time and energy. The composite particles are suitable for use in inhalable pharmaceutical compositions.

- 1 -

Method of making particles for use in a
pharmaceutical composition

The present invention relates to particles and to methods
5 of making particles. In particular, the invention relates to
methods of making composite excipient particles comprising a
pharmaceutical excipient material.

It is known to administer to patients drugs in the form
of fine particles. For example, in pulmonary administration a
10 particulate medicament composition is inhaled by the patient.
Pulmonary administration is particularly suitable for
medicaments which are intended to cure or alleviate
respiratory conditions such as asthma and for medicaments
which are not suitable for oral ingestion such as certain
15 biological macromolecules. Known devices for the
administration of drugs to the respiratory system include
pressurised metered dose inhalers (pMDI's) and dry powder
inhalers (DPI's).

In order that the particles be carried deep into the
20 lungs, the particles must be very fine, for example having a
mass median aerodynamic diameter of less than $10\mu\text{m}$.

Such small particles are, however, thermodynamically
unstable due to their high surface area to volume ratio, which
provides significant excess surface free energy and encourages
25 particles to agglomerate. In the inhaler, agglomeration of
small particles and adherence of particles to the walls of the
inhaler are problems that result in the active particles
leaving the inhaler as large agglomerates or being unable to
leave the inhaler and remaining adhered to the interior of the
30 inhaler.

In an attempt to improve that situation, dry powders for
use in dry powder inhalers often include particles of an
excipient material mixed with the fine particles of active
material. Such particles of excipient material may be coarse,

- 2 -

for example, having mass median aerodynamic diameters greater than 90μ , (such coarse particles are referred to as carrier particles) or they may be fine.

The step of dispersing the active particles from other
5 active particles and from the carrier particles, if present, to form an aerosol of fine active particles for inhalation is significant in determining the proportion of the dose of active material which reaches the desired site of absorption in the lungs. In order to improve the efficiency of that
10 dispersal it is known to include in the composition additive materials. Such additive materials are thought to reduce the attractive forces between the particles thereby promoting their dispersal.

WO 97/23485 discloses powders for inhalation comprising
15 carrier particles and an additive material for the promotion of the dispersal of the active particles from the carrier particles. The use of gentle milling of carrier particles of diameter 90 to $125\mu\text{m}$ in order to remove surface asperities which are suggested to be sites of high surface energy at
20 which active particles can be bound so tightly to the carrier particles that they are not released upon actuation of the inhaler is also disclosed. In some cases the carrier particles are gently milled in the presence of the additive material. However, in all cases, the milling treatment is a
25 gentle one such that the size of the carrier particles is not substantially changed.

The present invention provides a method for making composite excipient particles for use in a pharmaceutical composition, the method comprising a milling step in which
30 particles of an excipient material are milled in the presence of an additive material.

The additive material is an material which, when included in a dry powder formulation for inhalation, promotes the dispersal of the particles, particularly the active particles,

- 3 -

to form an aerosol upon actuation of the inhaler. Additive materials and dry powder formulations containing the additive materials are disclosed in WO 97/23485. The additive materials are, in particular, suitable for promoting the release (upon actuation of the inhaler) of the active particles from carrier particles when a dry powder comprising active particles, carrier particles and additive material is administered via a dry powder inhaler.

It will be understood that the additive material will be a different material to the excipient material.

It has been found that the milling of the particles of excipient material in the presence of an additive material produces significantly smaller particles and/or requires less time and less energy than the equivalent process carried out in the absence of the additive material. Using the method of the invention, it has been possible to produce composite excipient particles which have a mass median aerodynamic (MMAD) or a volume median diameter (VMD) of less than $1\mu\text{m}$. It is often not possible to make such small particles by other milling methods. Furthermore, when the composite excipient particles are included in a pharmaceutical composition the additive material promotes the dispersal of the active particles on administration of that composition to the patient, for example, via actuation of a dry powder inhaler device. ("Actuation of a dry powder inhaler device" refers to the process during which a dose of the powder is removed from its rest position in the inhaler device, usually by a patient inhaling. That step takes place after the powder has been loaded into the dry powder inhaler device ready for use.) The degree of that promotion of dispersal has been found to be enhanced in comparison to a composition made by simple blending of similar sized particles of excipient material with additive material. This is believed to be because the method of the invention produces improved distribution of the

- 4 -

additive material on the surfaces of the excipient particles.

The particles of excipient material may comprise more than 50% by weight of excipient material, preferably more than 80% by weight, more preferably more than 95% by weight of
5 excipient material. The particles of excipient material preferably consists essentially of excipient material.

The method of the invention produces composite excipient particles.

The composite excipient particles are particles of
10 excipient material which have, upon their surfaces, an amount of the additive material. That amount of additive material may be very small, for example, in the case where the additive material is present as a solution which is removed after the milling step leaving only a residue of additive material upon
15 the surface of the active or excipient particles.

The additive material may be in the form of a coating on the surfaces of the particles of excipient material. The coating may be a discontinuous coating. The additive material may be in the form of particles adhering to the surfaces of
20 the particles of excipient material.

The pharmaceutical composition may be any pharmaceutical composition which comprises an excipient material in the form of small particles, for example, particles of mass median aerodynamic diameter of less than $50\mu\text{m}$.

25 The word "milling" as used herein refers to any mechanical process which applies sufficient force to the particles of excipient material that it is capable of breaking coarse particles (for example, particles of mass median aerodynamic diameter greater than $100\mu\text{m}$) down to fine
30 particles of mass median aerodynamic diameter not more than $50\mu\text{m}$. For example, the milling step may be one which if the excipient particles were replaced with the same weight of lactose having a MMAD of between 150 and $200\mu\text{m}$ would be capable of reducing the MMAD of that lactose to below $50\mu\text{m}$.

- 5 -

It has been found that processes which do not apply that degree of force are not effective in the method of the invention. It is believed that is because that degree of force is required to separate the individual particles of excipient material such that effective mixing and effective application of the additive material to the surfaces of those particles is achieved. It should be understood, however, that in the case where the particles of excipient material are already fine, for example, having a mass median aerodynamic diameter below 60μ prior to the milling step, the size of those particles may not be significantly reduced. The important thing is that the milling process applies a sufficiently high degree of force or energy to the particles.

A wide range of milling devices and conditions are suitable for use in the method of the invention. The selection of appropriate milling conditions, for example, intensity of milling and duration, to provide the required degree of force will be within the ability of the skilled person who will understand how to arrange those milling conditions such that the milling is capable of breaking down coarse particles, as mentioned above. Ball milling is a preferred method. Alternatively, a high pressure homogeniser may be used in which a fluid containing the particles is forced through a valve at high pressure producing conditions of high shear and turbulence. Shear forces on the particles, impacts between the particles and machine surfaces or other particles and cavitation due to acceleration of the fluid may all contribute to the fracture of the particles. Such homogenisers may be more suitable than ball mills for use in large scale preparations of the composite excipient particles. Suitable homogenisers include the EmulsiFlex high pressure homogeniser which is capable of pressure up to 4000 Bar, Niro Soavi high pressure homogenisers (capable of pressures up to 2000 Bar), and the Microfluidics Microfluidiser (maximum

- 6 -

pressure 2750 Bar). The milling step may, alternatively, involve an agitator bead mill, for example, the DYNO-mill (Willy A. Bachofen AG, Switzerland) or the Netzsch high energy media mill. The Mechano-Fusion system (Hosokawa Micron Ltd) and the Hybridizer (Nara) are also suitable for use with the invention. Other possible milling devices include air jet mills, pin mills, hammer mills, knife mills and ultracentrifugal mills. Preferably, the milling process is a sealed process, preventing the escape of the additive material as fine particles or as a vapour. Jet milling may be used but in some cases additive material can be lost from the jet mill, for example, when the additive material is of very small particles, e.g. less than $1\mu\text{m}$ in diameter.

Where the excipient material is in the form of coarse particles prior to the milling step their size will be substantially reduced during the milling step.

The mass median aerodynamic diameter of the particles of excipient material may be substantially reduced during the milling step. More preferably the mass median aerodynamic diameter (MMAD) of the particles of excipient material is reduced 10%, advantageously by at least 20%, preferably by at least 50%, more preferably by at least 70% during the milling step.

After the milling step, the mass median aerodynamic diameter of the composite excipient particles is preferably not more than $50\mu\text{m}$, advantageously not more than $20\mu\text{m}$, more preferably not more than $15\mu\text{m}$ and especially preferably not more than $10\mu\text{m}$. Furthermore, 90% by weight of the composite excipient particles may have a diameter of less than $50\mu\text{m}$, advantageously less than $20\mu\text{m}$, more preferably less than $15\mu\text{m}$ and especially preferably less than $10\mu\text{m}$. The mass median aerodynamic diameter of the composite excipient particles will, in general not be less than $0.1\mu\text{m}$.

- 7 -

The milling step may be carried out in a closed vessel, for example in a ball mill. The use of a closed vessel prevents loss of ultrafine particles or vapour of the additive material which has been found to occur in jet milling or other open processes. The milling may be dry, that is to say, there is no liquid present and the mixture to be milled is in the form of a dry particulate. Preferably, the milling is wet, that is, the milling step is carried out in the presence of a liquid. The liquid medium may be aqueous or non-aqueous, high or low volatility and of any solid content as long as it does not dissolve the excipient particles to any significant degree and its viscosity is not so high that it prevents motion of the balls. The additive material is preferably not dissolved in the liquid but is present in the form of particles.

However, the additive material may be soluble in the liquid medium in which case it will be present as a solution during the milling step and will adsorb to the particle surfaces. The presence of a liquid medium helps to prevent compacting of the particles of excipient material on the walls of the vessel and may also allow the more even spreading of the additive material on the surface of the particles of excipient material as compared to dry milling. Preferably, the method also comprises the step of removing the liquid after the milling step. That may be accomplished by sieving followed by spray drying, or by evaporation of the liquid (followed by milling, if necessary, to break up large aggregates or cakes of material or by freeze drying). Preferably, the liquid is removed by spray drying.

As mentioned above, the composite excipient particles produced after the milling step may be of a suitable size for use in a pharmaceutical composition, for example, a powder or suspension for inhalation. However, it may also be desirable for the composite excipient particles to be smaller than that and to have after the milling step an agglomeration step in

- 8 -

which the particles of excipient material are agglomerated to form agglomerated particles. In that way agglomerates of a size tailored to the requirement may be produced. Preferably, the agglomeration step is a spray drying step. The spray
5 drying conditions may be selected to produce droplets having a desired size in the range of 1000 μ m to 0.5 μ m. The size of the agglomerates produced will depend largely on the concentration of the composite excipient particles in the spray feed and the droplet size. Other materials, for example, binders may be
10 included in the spray feed. Where the milling step is wet milling, the suspension or slurry may be spray dried directly after the milling step. Agglomeration may also be conducted in a fluid bed dryer or granulator.

The optimum amount of additive material will depend on
15 the chemical composition and other properties of the additive material and upon the nature of the excipient material. In general, the amount of additive material in the composite particles will be not more than 60% by weight, based on the weight of the excipient material. However, it is thought that
20 for most additive materials the amount of additive material should be in the range of 40% to 0.25%, preferably 30% to 0.5%, more preferably 20% to 2%, based on the total weight of the additive material and the excipient material being milled. In general, the amount of additive material is at least 0.01%
25 by weight based on the total weight of the additive material and the excipient material being milled.

Where additive material is lost in the process, for example, as particles carried away in the filtrate when a liquid milling medium is filtered off, it may be necessary to
30 add more additive material at the start of the milling step than is desired in the composite excipient particles.

Advantageously the additive material is an anti-adherent material and will tend to decrease the cohesion between the composite excipient particles and between the composite

- 9 -

excipient particles and any other particles present in the pharmaceutical composition.

Advantageously the additive material is an anti-friction agent (glidant) and will give better flow of the
5 pharmaceutical composition in, for example, a dry powder inhaler which will lead to a better dose reproducibility.

Where reference is made to an anti-adherent material, or to an anti-friction agent, the reference is to include those materials which are able to decrease the cohesion between the
10 particles, or which will tend to improve the flow of powder in an inhaler, even though they may not usually be referred to as anti-adherent material or an anti-friction agent. For example, leucine is an anti-adherent material as herein defined and is generally thought of as an anti-adherent
15 material but lecithin is also an anti-adherent material as herein defined, even though it is not generally thought of as being anti-adherent, because it will tend to decrease the cohesion between the composite excipient particles and between the composite excipient particles and any other particles
20 present in the pharmaceutical composition.

Advantageously, the additive material consists of physiologically acceptable material.

The additive material may include a combination of one or more materials.

25 It will be appreciated that the chemical composition of the additive material is of particular importance. Preferably, the additive material is a naturally occurring animal or plant substance.

Advantageously, the additive material includes one or
30 more compounds selected from amino acids and derivatives thereof, and peptides and polypeptides having molecular weight from 0.25 to 1000Kda, and derivatives thereof. Amino acids, peptides or polypeptides and derivatives of peptides and polypeptides are both physiologically acceptable and give

- 10 -

acceptable release of the active particles on inhalation.

It is particularly advantageous for the additive material to comprise an amino acid. The additive material may comprise one or more of any of the following amino acids: leucine, 5 isoleucine, lysine, valine, methionine, phenylalanine. The additive may be a salt or a derivative of an amino acid, for example aspartame or acesulfame K. Preferably, the additive particles consist substantially of an amino acid, more preferably of leucine, advantageously L-leucine. The D- and 10 DL-forms may also be used. As indicated above, leucine has been found to give particularly efficient dispersal of the active particles on inhalation.

The additive material may include one or more water soluble substances. This helps absorption of the substance by 15 the body if the additive reaches the lower lung. The additive material may include dipolar ions, which may be zwitterions.

Alternatively, the additive material may comprise a phospholipid or a derivative thereof. Lecithin has been found to be a good material for the additive material.

20 Preferably, the additive material comprises a metal stearate, or a derivative thereof, for example, sodium stearyl fumarate or sodium stearyl lactylate. Advantageously, the additive material comprises a metal stearate. For example, magnesium stearate, calcium stearate, sodium stearate or 25 lithium stearate. Preferably, the additive material comprises magnesium stearate.

The additive material may include or consist of one or more surface active materials, in particular materials that are surface active in the solid state, which may be water 30 soluble, for example lecithin, in particular soya lecithin, or substantially water insoluble, for example solid state fatty acids such as oleic acid, lauric acid, palmitic acid, stearic acid, erucic acid, behenic acid, or derivatives (such as esters and salts) thereof such as glyceryl behenate. Specific

- 11 -

examples of such materials are: phosphatidylcholines, phosphatidylglycerols and other examples of natural and synthetic lung surfactants; Liposomal formulations; lauric acid and its salts, for example, sodium lauryl sulphate, 5 magnesium lauryl sulphate; triglycerides such as Dynsan 118 and Cutina HR; and sugar esters in general.

Other possible additive materials include talc, titanium dioxide, aluminium dioxide, silicon dioxide and starch.

The additive material preferably comprises one or more 10 materials selected from the group consisting of amino acids, lecithins, phospholipids and metal stearates (especially magnesium stearate).

It should be understood that, whilst the above discussion of the additive material has related primarily to the use of 15 those additive materials in pharmaceutical compositions for dry powder inhalers, the composite excipient particles of the present invention are suitable for use in any pharmaceutical composition which requires the dispersal of small particles of active material into an aerosol cloud. The composite 20 excipient particles are therefore especially suitable for use in pharmaceutical compositions which are administered as an aerosol or cloud. Such compositions include powders for dry powder inhalers, suspensions for use in pressurised metered dose inhalers.

25 The terms "active particles" and "particles of active material" are used interchangeably herein. The active particles referred to throughout the specification will comprise one or more pharmacologically active agents. The active particles advantageously consist essentially of one or 30 more pharmacologically active agents. Suitable pharmacologically active agents may be materials for therapeutic and/or prophylactic use. Active agents which may be included in the formulation include those products which are usually administered orally by inhalation for the

- 12 -

treatment of disease such as respiratory disease, for example, β -agonists.

The active particles may comprise at least one β_2 -agonist, for example one or more compounds selected from
5 terbutaline, salbutamol, salmeterol and formoterol. If
desired, the active particles may comprise more than one of
those active agents, provided that they are compatible with
one another under conditions of storage and use. Preferably,
the active particles are particles of salbutamol sulphate.
10 References herein to any active agent are to be understood to
include any physiologically acceptable derivative. In the
case of the β_2 -agonists mentioned above, physiologically
acceptable derivatives include especially salts, including
sulphates.

15 The active particles may be particles of ipatropium
bromide.

The active particles may include a steroid, which may be
beclometasone dipropionate or may be fluticasone. The active
principle may include a cromone which may be sodium
20 cromoglycate or nedocromil. The active principle may include
a leukotriene receptor antagonist.

The active particles may include a carbohydrate, for
example heparin.

The active particles may advantageously comprise a
25 therapeutically active agent for systemic use being
advantageously capable of being absorbed into the circulatory
system via the lungs. For example, the active particles may
comprise peptides or polypeptides or proteins such as DNase,
leukotrienes or insulin (including substituted insulins and
30 pro-insulins), cyclosporin, interleukins, cytokines, anti-
cytokines and cytokine receptors, vaccines (including
influenza, measles, 'anti-narcotic' antibodies, meningitis),
growth hormone, leuprolide and related analogues, interferons,
desmopressin, immunoglobulins, erythropoietin, calcitonin

- 13 -

and parathyroid hormone. The pharmaceutical compositions of the invention may in particular have application in the administration of insulin to diabetic patients, thus avoiding the normally invasive administration techniques used for that agent.

The composite excipient particles of the invention may advantageously be for use in pain relief. Non-opioid analgesic agents that may be included as pain relief agents are, for example, alprazolam, amitriptyline, aspirin, baclofen, benzodiazepines, bisphosphonates, caffeine, calcitonin, calcium-regulating agents, carbamazepine, clonidine, corticosteroids, dantrolene, dexamethasone, disodium pamidronate, ergotamine, flecainide, hydroxyzine, hyoscine, ibuprofen, ketamine, lignocaine, lorazepam, methotrimeprazine, methylprednisolone, mexiletine, mianserin, midazolam, NSAIDs, nimodipine, octreotide, paracetamol, phenothiazines, prednisolone, somatostatin. Suitable opioid analgesic agents are: alfentanil hydrochloride, alphaprodine hydrochloride, anileridine, bezitramide, buprenorphine hydrochloride, butorphanol tartrate, carfentanil citrate, ciramadol, codeine, dextromoramide, dextropropoxyphene, dezocine, diamorphine hydrochloride, dihydrocodeine, dipipanone hydrochloride, enadoline, eptazocine hydrobromide, ethoheptazine citrate, ethylmorphine hydrochloride, etorphine hydrochloride, fentanyl citrate, hydrocodone, hydromorphone hydrochloride, ketobemidone, levomethadone hydrochloride, levomethadyl acetate, levorphanol tartrate, meptazinol hydrochloride, methadone hydrochloride, morphine, nalbuphine hydrochloride, nicomorphine hydrochloride, opium, hydrochlorides of mixed opium alkaloids, papaveretum, oxycodone, oxymorphone hydrochloride, pentamorphine, pentazocine, pethidine hydrochloride, phenazocine hydrobromide, phenoperidine hydrochloride, piconadol hydrochloride, piritramide, propiram fumarate, remifentanil

- 14 -

hydrochloride, spiradoline mesylate, sufentanil citrate, tilidate hydrochloride, tonazocine mesylate, tramadol hydrochloride, trefentanil. Illustrative of the application of the invention in relation to formulations for pain relief are
5 formulations containing composite particles comprising fentanyl citrate as analgesic or comprising agents for the treatment of migraine, for example, dihydroergotamine mesylate.

The composite particles could also be used in
10 formulations for the local administration of agents, for example, for anti cancer activity, anti-virals, antibiotics, muscle relaxants, antidepressants, antiepileptics or vaccines.

The term excipient as used herein refers to any solid, generally pharmaceutically inert material which is acceptable
15 for inclusion in pharmaceutical formulations. The excipient material may be composed of one or more materials selected from sugar alcohols; polyols, for example sorbitol, mannitol and xylitol, and crystalline sugars, including monosaccharides and disaccharides; inorganic salts such as sodium chloride and
20 calcium carbonate; organic salts such as sodium lactate; and other organic compounds such as urea, polysaccharides, for example starch and its derivatives; oligosaccharides, for example cyclodextrins and dextrans. Advantageously the excipient material is a crystalline sugar, for example, a
25 monosaccharide such as glucose or arabinose, or a disaccharide such as maltose, saccharose, dextrose or lactose. Preferably, the excipient material is of lactose.

The invention also provides composite excipient particles for use in a pharmaceutical composition, preferably a
30 pharmaceutical composition for inhalation, more preferably a powder for a dry powder inhaler.

The invention further provides composite excipient particles for use in a pharmaceutical composition each composite excipient particle comprising a particle of an

- 15 -

excipient material and additive material on the surface of that particle of excipient material, the composite excipient particles having a mass median aerodynamic diameter of less than $20\mu\text{m}$. Preferably, the composite excipient particles have
5 a MMAD of not more than $15\mu\text{m}$, advantageously not more than $10\mu\text{m}$ and more preferably not more than $5\mu\text{m}$. Furthermore, 90% by weight of the composite excipient particles may have a diameter of less than $50\mu\text{m}$, advantageously less than $20\mu\text{m}$, more preferably less than $15\mu\text{m}$, more advantageously less than
10 $10\mu\text{m}$ and especially advantageously less than $5\mu\text{m}$.

It will be understood that persons skilled in the art are able to convert in an approximate manner between mass, volume, aerodynamic, surface, number based and other diameters.

MMAD may be determined using an impinger, for example, a
15 multi-stage liquid impinger. Volume median diameters and measurements of the proportion of particles having a diameter less than a certain value may be determined by the Malvern laser light scattering method.

The invention further provides a pharmaceutical
20 composition comprising composite excipient particles. Preferably, the pharmaceutical composition is a dry powder and is suitable for use in a dry powder inhaler. Such pharmaceutical compositions may comprise essentially only the composite excipient particles and active particles or they may
25 comprise additional ingredients such as carrier particles and flavouring agents. Carrier particles may be of any acceptable excipient material or combination of materials. For example, the carrier particles may be composed of one or more materials selected from sugar alcohols, polyols and crystalline sugars.
30 Other suitable carriers include inorganic salts such as sodium chloride and calcium carbonate, organic salts such as sodium lactate and other organic compounds such as polysaccharides and oligosaccharides. Advantageously the carrier particles are of a polyol. In particular the carrier particles may be

- 16 -

particles of a crystalline sugar, for example, mannitol dextrose or lactose. Preferably, the carrier particles are of lactose.

Advantageously, substantially all (by weight) of the carrier particles have a diameter which lies between 20 μ m and 1000 μ m, more preferably 50 μ m and 1000 μ m. Preferably, the diameter of substantially all (by weight) of the carrier particles is less than 355 μ m and lies between 20 μ m and 250 μ m. Preferably at least 90% by weight of the carrier particles have a diameter between from 60 μ m to 180 μ m. The relatively large diameter of the carrier particles improves the opportunity for other, smaller particles to become attached to the surfaces of the carrier particles and to provide good flow and entrainment characteristics and improved release of the active particles in the airways to increase deposition of the active particles in the lower lung.

The ratio in which the carrier particles (if present), composite excipient particles and active particles are mixed will, of course, depend on the type of inhaler device used, the type of active particles used and the required dose.

Where carrier particles are included in the pharmaceutical composition, the composite excipient particles are preferably present in an amount of from 1% to 40%, more preferably 5% to 20% based on the weight of the carrier particles. The carrier particles are preferably present in an amount of at least 50%, more preferably 60%, advantageously 75% based on the combined weight of the active particles, the composite particles and the carrier particles.

The carrier particles preferably have a relatively highly fissured surface, that is, on which there are clefts and valleys and other recessed regions, referred to herein collectively as fissures. The fissures should preferably be at least 5 μ m wide extending to at least 5 μ m deep, preferably at least 10 μ m wide and 10 μ m deep and most preferably at least 20 μ m

- 17 -

wide and 20 μ m deep. The fissured carrier particles offer particular advantages in that they are capable of retaining relatively large amounts of fines (the word "fines" refers to the combined active particles and composite excipient particles) in the fissures without or with only little segregation. That is thought to underly the good respirable fraction that is generated in use of the formulations.

Advantageously, the fines content is not more than 50% by weight, and more preferably not more than 20% by weight, based on the total weight of fines and carrier particles. Preferably, the fines content is at least 5% by weight, based on the total weight of fines and carrier particles. The invention offers particular advantages in the case of formulations containing at least 10%, for example, from 10 to 20% by weight fines or at least 20%, for example from 20 to 50% by weight fines, in each case, based on the total weight of fines and carrier particles. The fines content may include from 0.1 to 90% by weight active particles, and from 0.1 to 99% by weight of composite excipient particles, in each case based on the total weight of fines. In many cases, however, the active particles will constitute less than half of the total weight of fines.

A number of methods may be used to determine whether carrier particles have a fissured surface that will offer the above-mentioned capability of retaining relatively large fines contents substantially without segregation:

1. Determination of tapped density.

The tapped density of the fissured carrier particles may be about 6% or more, and preferably 15% or more, lower than the tapped density of carrier particles of the same material and of particle characteristics of a kind typical of carrier particles which have conventionally been used in the manufacture of inhalable powders. In the case of fissured carrier particles of crystalline sugars, for example lactose,

- 18 -

the tapped density of the fissured particles is not more than 0.75g/cm³, and preferably not more than 0.70g/cm³. The tapped density of lactose grades conventionally used in the manufacture of commercial DPI formulations is typically about 0.8g/cm³. Tapped densities referred to herein may be measured as follows:

A measuring cylinder is weighed on a top pan balance (2 place). Approximately 50g powder is introduced into the measuring cylinder, and the weight is recorded. The measuring cylinder containing the powder is attached to a jolting volumeter (Jel Stampfvolumeter). The jolting volumeter is set to tap 200 times. During each tap, the measuring cylinder is raised and allowed to fall a set distance. After the 200 taps, the volume of the powder is measured. The tapping is repeated and the new volume measured. The tapping is continued until the powder will settle no more. The tapped density is calculated as the weight of the powder divided by the final tap volume. The procedure is performed three times (with new powder each time) for each powder measured, and the mean tapped density calculated from those three final tapped volume values.

2. Mercury Intrusion Porosimetry. Mercury intrusion porosimetry assesses the pore size distribution and the nature of the surface and pore structure of the particles. Porosimetry data is suitably collected over pressure range 3.2kPa to 8.7MPa, for example, using an Autopore 9200 II Porosimeter (Micromeritics, Norcross, USA). Samples should be evacuated to below 5Pa prior to analysis to remove air and loosely bound surface water. Suitable lactose is characterised by a bulk density of not more than 0.65g/cm³ and preferably not more than 0.6g/cm³. Suitable lactose is also characterised by a total intrusion volume measured by mercury intrusion porosimetry of at least 0.8cm³g⁻¹ and preferably at least 0.9cm³g⁻¹. (It has been found that lactose having a

- 19 -

bulk density of 0.6g/cm³ as measured by mercury intrusion porosimetry has a tapped density of about 0.7g/cm³, whereas the discrepancy between the two methods at lower densities is less.)

5 3. "Fissure Index". The term "fissure index" used herein refers to the ratio of a theoretical envelope volume of the particles, as calculated from the envelope of the particles, to the actual volume of the carrier particles, that is, omitting fissures within the envelope. Suitable carrier
10 particles are those having a fissure index of at least 1.25. The theoretical envelope volume may be determined optically, for example, by examining a small sample of the particles using an electron microscope. The theoretical envelope volume of the particles may be estimated via the following method.
15 An electron micrograph of the sample may be divided into a number of grid squares of approximately equal populations, each containing a representative sample of the particles. The population of one or more grids may then be examined and the envelope encompassing each of the particles determined
20 visually as follows. The Feret's diameter for particles within a grid is measured relative to a fixed axis of the image. Typically at least ten particles are measured for their Feret's diameter. Feret's diameter is defined as the length of the projection of a particle along a given reference
25 line as the distance between the extreme left and right tangents that are perpendicular to the reference line. A mean Feret's diameter is derived. A theoretical mean envelope volume may then be calculated from this mean diameter to give a representative value for all the grid squares and thus the
30 whole sample. Division of that value by the number of particles gives the mean value per particle. The actual volume of the particles may then be calculated as follows. First, the mean mass of a particle is calculated. A sample of approximately 50mg is taken and its precise weight recorded to

- 20 -

0.1mg. Then by optical microscopy the precise number of particles in that sample is determined. The mean mass of one particle can then be determined. The procedure is then repeated five times to obtain a mean value of this mean.

5 Second, a fixed mass of particles (typically 50g), is weighed out accurately, and the number of particles within this mass is calculated using the above mean mass value of one particle. Finally, the sample of particles is immersed in a liquid in which the particles are insoluble and, after agitation to
10 remove trapped air, the amount of liquid displaced is measured. From this the mean actual volume of one particle can be calculated. The fissure index is advantageously not less than 1.5, and is, for example, 2 or more.

4. "Rugosity Coefficient". The rugosity coefficient is used
15 to mean the ratio of the perimeter of a particle outline to the perimeter of the 'convex hull'. This measure has been used to express the lack of smoothness in the particle outline. The 'convex hull' is defined as a minimum enveloping boundary fitted to a particle outline that is nowhere concave.
20 (See "The Shape of Powder-Particle Outlines" A. E. Hawkins, Wiley.) The 'rugosity coefficient' may be calculated optically as follows. A sample of particles should be identified from an electron micrograph as identified above. For each particle the perimeter of the particle outline and
25 the associated perimeter of the 'convex hull' is measured to provide the rugosity coefficient. This should be repeated for at least ten particles to obtain a mean value. The mean rugosity coefficient is at least 1.25.

Carrier particles which have the above-mentioned
30 capability of retaining relatively large amounts of fine material without or with only little segregation will generally comply with all of Methods 1 to 4 above, but for the avoidance of doubt any carrier particles which comply with at

- 21 -

least one of Methods 1 to 4 is deemed to be a fissured particle.

The carrier particles are advantageously in the form of an agglomerate consisting of a plurality of crystals fused to one another, the fastness of agglomeration being such that the carrier particles have substantially no tendency to disintegrate on expulsion from the inhaler device. In the case of crystalline sugars, such as lactose, such structures may be obtained in a wet granulation process, in which crystals within an agglomerate become fused to one another by solid bridges, the resultant structure having a complex shape of high irregularity and/or high fractal dimension, including a multiplicity of clefts and valleys, which in some cases may be relatively deep. Each agglomerate will generally contain at least three lactose primary crystals of the characteristic tomahawk shape.

Such agglomerates are clearly distinguished from agglomerates of the kind which form in powder formulations by aggregation of particles, which do tend to disintegrate on expulsion from the inhaler.

Where the carrier particles are fissured carrier particles, they will preferably have a MMAD of at least $175\mu\text{m}$, more preferably at least $200\mu\text{m}$.

Suitably shaped carrier particles also include dendritic spherulites of the type disclosed in US 4349542 for use in tablet manufacture.

Where the pharmaceutical composition is a powder for use in a dry powder inhaler and does not comprise carrier particles the composite excipient particles are preferably present in an amount of at least 1%, more preferably at least 5%, advantageously at least 10% and most preferably at least 20% by weight based on the combined weights of the composite excipient particles and the active particles. The composite excipient particles will preferably be present in an amount of

- 22 -

not more than 95%, more preferably not more than 90% and especially advantageously not more than 70% based on the combined weights of the composite excipient particles and the active particles.

5 The pharmaceutical composition may comprise a propellant and be suitable for use in a pressurised metered dose inhaler.

 The invention also provides the use of an additive material as a milling aid in the milling of particles of an excipient material. The term milling aid should be understood
10 to refer to a substance which reduces the amount of energy required to mill the particles of excipient material.

 Embodiments of the invention will now be described for the purposes of illustration only.

 Evaluation of the fine particle fraction of multi-stage
15 liquid impinger (MSLI) was carried out in accordance with method given in European Pharmacopoeia, Supplement 2000, Section 2.9.18.

 Evaluation of the fine particle fraction using a twin stage liquid impinger (TSI) was carried out in accordance with
20 the method of WO 96/23485 pages 29 to 33. The method is also described in the European Pharmacopoeia referred to above and in J. Pharm. Pharmacol, 1987, 39, 966-972).

 All percentages are by weight unless indicated otherwise.

25 Composite Excipient Particles

Method 1

 98g of Microfine (MMAD approximately 8 μ m) lactose
30 (manufactured by Borculo) was placed in a stainless steel milling vessel. 300g of stainless steel milling balls varying from 10 to 3mm diameter were added. 2g of additive material was added and the vessel was located in a Retsch S100 Centrifugal Mill. The powder was milled for 30 minutes at 580

- 23 -

rpm and was then sieved to remove the milling balls. Each of the following additive materials were used in turn: magnesium stearate, calcium stearate, sodium stearate, lithium stearate, stearic acid, stearylamine, soya lecithin, sodium stearyl
5 fumarate, l-leucine, l-iso-leucine, oleic acid, starch, diphosphatidyl choline, behenic acid, glyceryl behenate and sodium benzoate. Pharmaceutically acceptable fatty acids and derivatives, waxes and oils may also be used (where those materials are sticky, they should be used at levels where
10 their stickiness does not inhibit the flow of the powder).

Method 2

95g of Microfine lactose (Borculo) was placed in a
15 ceramic milling vessel (manufactured by the Pascall Engineering Company). 5g of additive material and the ceramic milling balls were added. The ball mill was tumbled at 60 rpm for 5 hours. This was repeated a number of times with the amount of additive material varied as a percentage of the
20 lactose from 0.25 to 20%. Additive materials used were L-leucine and magnesium stearate.

The powder was recovered by sieving to remove the milling balls.

25 Method 3

Experiments were performed to produce co-processed powders of fine lactose and additive material (l-leucine) in a Gem-T jet mill. Quantities of L-leucine were varied from 0.5
30 to 10% based on the weight of the lactose. Lactoses used included Lactochem Regular (having a broad distribution of particle sizes over 1-200 μ m) and Microfine (Borculo). The mill was operated normally.

- 24 -

Method 4

Method 3 was repeated using magnesium stearate in place of l-leucine.

5

Method 5

The experiments of Methods 3 and 4 were repeated using a Retsch ZM100 Ultra-Centrifugal Mill.

10

Method 6

Leucine was micronised in a jet mill and blended with Microfine lactose (Borculo) in a high shear mixer (Morphy Richards food processor) or in a Retsch ZM100 Ultra-Centrifugal mill. Quantities of L-leucine were varied from 0.5 to 10% based on the weight of the lactose.

Methods 3, 5 and 6 (where leucine is used) are less favoured methods, as the powders frequently performed only slightly better than with equivalent powders comprising unmodified lactoses. This is believed to be because the mills used were not sealed allowing the leucine to escape as fine particles or as vapour. In method 4, (using magnesium stearate, which is not as volatile as leucine), the powders performed well.

It was observed in some cases that when ball milling according to Methods 1 and 2, a fine powder was not produced. Instead the powder was compacted on the walls of the mill by the action of the mill. That inhibited the milling action and prevented the preparation of the composite excipient particles. That problem occurred particularly when certain additive materials were used, in cases where the additive material was present in small proportions (typically <2%), in cases where the milling balls were relatively small (typically

- 25 -

<3mm), in cases where the milling speed was too slow and where the starting lactose was too fine. To prevent this occurring it is advantageous to mill in a liquid medium. The liquid medium reduces the tendency to compaction, assists the dispersal of additive material with lactose and improves any milling action.

Method 7

2g leucine with 98g of ultra-fine micronised lactose (mass median diameter approximately $3\mu\text{m}$) was placed in a stainless steel milling vessel. 300g of stainless steel milling balls varying from 10 to 3mm diameter were added. The vessel was located in a Retsch S100 Centrifugal Mill. The powder was milled for 10 minutes at 580 rpm and was found to have compacted on the sides of the vessel, and consequently co-milling was not possible. Compaction also occurred when magnesium stearate was used as additive material. Sufficient cyclohexane was added to the vessel to create a loose paste and the co-milling was continued successfully in that liquid medium. The excipient powder was recovered by drying the paste, milling the powder for 2 minutes and sieving.

Method 8

25

10g of Microfine lactose (Borculo) was combined with 1g of sodium stearate and 10cm³ cyclohexane. 50g of 5mm balls were added and the mixture was milled for 90 minutes. The powder was recovered by leaving the paste in a fume hood overnight to evaporate the cyclohexane and then ball milling for 1 minute. Powders having lecithin, PVP, Span 80, magnesium stearate and leucine in place of sodium stearate were prepared by this method. Quantities of additive material were usually 10% by weight based on weight of lactose but were

- 26 -

also varied from 1% to 60%. The experiments were also repeated using dichloromethane as liquid medium.

Method 9

5

47.5g of Sorbalac 400 (Meggle) was combined with 2.5g of magnesium stearate and 50cm³ dichloromethane. 620g 3mm stainless steel balls were added to the mixture and the mixture was milled in a 250cm³ stainless steel pot at 500 rpm for 90 minutes in a Retsch S100 Centrifugal mill.

10

The excipient powder was recovered by drying the paste, milling the powder for 2 minutes and sieving to remove the steel balls.

This method was repeated using leucine in place of magnesium stearate.

15

Pharmaceutical Compositions comprising composite excipient particles

20 Composition 1

0.9g of composite excipient particles made by method 2 containing 5% l-leucine in Microfine lactose was blended with 0.6g of micronised budesonide by hand in a mortar. This blending could also be performed, for example, in a high shear blender, or in a ball mill or in a centrifugal mill. The resulting powder may be used in an inhaler directly, although in this example a sample of this powder was blended with a coarse carrier lactose (355 to 600µm) by tumbling in order to improve the powder flow properties. The powder was fired from a Cyclohaler at a flow rate of 60 litre per minute in a multi-stage liquid impinger. The fine particle fraction (<5µm) was 45%.

30

35

- 27 -

Composition 2

1g of micronised salbutamol sulphate was added to 1g of composite excipient particles made by method 1 containing 2% lecithin, and to 8g of a coarse carrier lactose. The mixture was tumbled for 30 minutes at 42 rpm. The resulting power was fired from a Cyclohaler at a flow rate of 60 litres per minute into a twin-stage impinger, giving a fine particle fraction (<5 microns) of about 44%. A similar example with a 2% leucine precursor gave a fine particle fraction (<5 μ m) of 52%.

Composition 3

The wet milled composite excipient particles have given particularly good results.

0.5g of micronised salbutamol sulphate was added to 0.5g of composite excipient particles made by method 7 containing 10% magnesium stearate, and to 4g of a coarse carrier lactose. This was tumbled for 30 minutes at 62 rpm. The resulting powder was fired from a Cyclohaler at a flow rate of 60 litres per minute into a twin-stage impinger, giving a fine particle fraction (<5 μ m) of 57%. The experiment was repeated using composite excipient particles containing 20% magnesium stearate and similar results were obtained.

25

Composition 4

0.5g of micronised salbutamol sulphate, 0.25g of g of composite excipient particles made by method 7 containing 10% magnesium stearate, 0.25g of g of composite excipient particles made by method 7 containing 10% leucine, and 4g of a coarse carrier lactose were all combined. The mixture was tumbled for 30 minutes at 62 rpm. The resulting powder was fired from a Cyclohaler at a flow rate of 60 litres per minute

- 28 -

into a twin-stage impinger, giving a fine particle fraction (<5 μ m) of ~65%.

Composition 5

5

0.5g of micronised salbutamol sulphate, 0.25g of composite excipient particles made by method 7 containing 10% lecithin, 0.25g of composite excipient particles made by method 7 containing 10% leucine, and 4g of a coarse carrier lactose were combined. The mixture was tumbled for 30 minutes at 62 rpm. The resulting powder was fired from a Cyclohaler at a flow rate of 60 litres per minute into a twin-stage impinger, giving a fine particle fraction (<5 μ m) of 68%.

15 Composition 6

0.5g of micronised salbutamol sulphate, 0.25g of composite excipient particles powder made by method 7 containing 10% lecithin, and 0.25g of g of composite excipient particles powder made by method 7 containing 10% sodium stearate, and 4g of a coarse carrier lactose were combined. The mixture was tumbled for 30 minutes at 62 rpm. The resulting powder was fired from a Cyclohaler at a flow rate of 60 litres per minute into a twin-stage impinger, giving a fine particle fraction (<5 μ m) of 65%.

Composition 7

0.25g micronised Fentanyl citrate, 5g of composite excipient particles made by method 9 and 44.75g of Prismalac (Meggler) 355-600 μ m sieve fraction lactose were combined in a Turbula mixer for 30 minutes at 60 rpm. The resulting powder was fired from a Cyclohaler at a flow rate of 90 litres min⁻¹

- 29 -

into a multistage liquid impinger giving a fine particle fraction ($<5\mu\text{m}$) of approximately 50%.

Composition 8

5

Composition 7 was repeated using double quantities of each material and replacing fentanyl citrate with with micronised budesonide. The fine particle fraction was approximately 50%.

10

Composition 9

Composition 8 was repeated using micronised dihydroergatamine mesylate in place of the budesonide. The fine particle fraction was approximately 60%.

It has been found to be particularly favourable to use a 355 to $600\mu\text{m}$ sieve fraction of Prismalac as the coarse carrier lactose. Segregation has not been observed in those formulations, even those comprising 10 and 20% magnesium stearate (i.e. up to 2% in the final composition).

When milling excipient material, it has been found to be preferable to use a large number of fine milling balls, rather than fewer heavy balls. The finer balls perform a more efficient co-milling action. Preferably the balls have a diameter of 5mm or less, advantageously 2mm or less. Liquid media are preferred which do not dissolve the excipient material and which evaporate rapidly and fully, for example non-aqueous liquids such as cyclohexane, ethanol, isopropanol or dichloromethane. Liquid media are preferred which are non flammable, for example dichloromethane and fluorinated hydrocarbons, especially fluorinated hydrocarbons which are suitable for use as propellants in inhalers.

- 30 -

A particularly preferred method is milling using a high pressure homogeniser, as this reduces contamination as compared to ball milling, for example, where the collisions between the balls may produce contaminants.

5 In the wet milling process, the additive material appears to confer several advantages: it allows the milling process to be more efficient, with smaller particles produced and compaction reduced, the particles may be stabilised in suspension, and on drying, the ternary agent remains as a
10 coating around the particles which may aid dispersion, and may modify the subsequent dissolution characteristics of the particle.

 When the active material is a protein, the milling may be preceded by lyophilisation (freeze drying) of the protein
15 either pure or in combination with an additive material and/or a polymeric stabiliser. The freeze drying may make them more brittle and more easily milled. The milling may need to be conducted under cryogenic (cold) conditions to increase the brittleness of the material.

- 31 -

Claims

1. A method for making composite excipient particles for use in a pharmaceutical composition, the method comprising a
5 milling step in which particles of an excipient material are milled in the presence of an additive material.
2. A method as claimed in claim 1, in which the mass median aerodynamic diameter of the particles of excipient material is substantially reduced during the milling step.
- 10 3. A method as claimed in claim 2, in which the mass median aerodynamic diameter (MMAD) of the particles of excipient material is reduced by at least 50% during the milling step.
4. A method as claimed in any of claims 1 to 3, in which, after the milling step, the mass median aerodynamic diameter
15 of the composite excipient particles is not more than 50 μ m.
5. A method as claimed in any preceding claim, in which the milling step is carried out in the presence of a liquid.
6. A method claimed in claim 5, which also comprises the step of removing the liquid after the milling step.
- 20 7. A method as claimed in claim 6, in which the liquid is removed by spray drying.
8. A method according to any preceding claim, which comprises, after the milling step, an agglomeration step in which the composite excipient particles are agglomerated to
25 form agglomerated particles.
9. A method as claimed in claim 8, in which the agglomeration step is a spray drying step.
10. A method as claimed in any preceding claim, wherein the excipient material is a crystalline sugar.
- 30 11. A method as claimed in any preceding claim, in which the additive material comprises an amino acid.
12. A method as claimed in any preceding claim, in which the additive material comprises a phospholipid.

- 32 -

13. A method as claimed in any preceding claim, in which the additive material comprises a metal stearate.
14. Composite excipient particles for use in a pharmaceutical composition as made by the method of any of claims 1 to 13.
- 5 15. Composite excipient particles for use in a pharmaceutical composition, each composite excipient particle comprising a particle of an excipient material and additive material on the surface of that particle of excipient material, the composite excipient particles having a mass median aerodynamic diameter
- 10 of less than $20\mu\text{m}$.
16. A pharmaceutical composition comprising composite excipient particles and active particles as made by a method according to any of claims 1 to 13 or as claimed in claim 15.
17. A pharmaceutical composition as claimed in claim 16 which
- 15 is a dry powder and is suitable for use in a dry powder inhaler.
18. A pharmaceutical composition as claimed in claim 17 which comprises carrier particles.
19. A pharmaceutical composition as claimed in claim 18 which
- 20 comprises the composite excipient particles in an amount of 1 to 40% based on the weight of the carrier particles.
20. A pharmaceutical composition as claimed in claim 18 or claim 19, in which the carrier particles have a fissured surface.
- 25 21. A pharmaceutical composition as claimed in any of claims 18 to 20, in which the carrier particles are of a crystalline sugar having a tapped density not exceeding 0.75g/cm^3 .
22. A pharmaceutical composition as claimed in any of claims 18 to 21, in which the carrier particles have a bulk density
- 30 as measured by mercury intrusion porosimetry of not exceeding 0.6g/cm^3 .
23. A pharmaceutical composition as claimed in any of claims 18 to 22, in which the carrier particles have a MMAD of at least $175\mu\text{m}$.
24. A pharmaceutical composition as claimed in

- 33 -

claim 16 which comprises a propellant and is suitable for use in a pressurised metered dose inhaler.

25. A dry powder for use in a dry powder inhaler comprising active particles, carrier particles for carrying the active
5 particles and composite excipient particles as made by the method of any of claims 1 to 13, or as claimed in claim 15, each of the composite excipient particles comprising a particle of excipient material having additive material on the surfaces of that particle of excipient material, the additive
10 material being suitable for the promotion of the release of the active particles from the carrier particles on actuation of the inhaler.

26. Use of an additive material as a milling aid in the milling of particles of an excipient material.

15 27. A method of making composite excipient particles for use in a pharmaceutical composition substantially as described herein.

28. Composite excipient particles for use in a pharmaceutical composition substantially as described herein.

20 29. A pharmaceutical composition substantially as described herein.

INTERNATIONAL SEARCH REPORT

International Application No.

PCT/GB 01/02860

A. CLASSIFICATION OF SUBJECT MATTER
 IPC 7 A61K9/14 A61K47/26

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, PAJ, BIOSIS

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 96 23485 A (CO ORDINATED DRUG DEV) 8 August 1996 (1996-08-08) cited in the application page 23, line 23 -page 25, line 14 examples 3-13 figures 4A,4B	1-6,8, 10-18, 26-29
X	EP 0 260 241 A (DRACO AB) 16 March 1988 (1988-03-16) examples 1,7	1,4,10, 12, 14-18, 26-29
X	WO 87 05213 A (CHIESI FARMA SPA) 11 September 1987 (1987-09-11) examples 1A,2	14, 16-18, 27-29
	--- -/-	

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents:

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- *G* document member of the same patent family

Date of the actual completion of the international search

9 October 2001

Date of mailing of the international search report

18/10/2001

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
 NL - 2280 HV Rijswijk
 Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
 Fax: (+31-70) 340-3016

Authorized officer

Epskamp, S

INTERNATIONAL SEARCH REPORT

International Application No
PCT/GB 01/02860

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 98 31346 A (MASSACHUSETTS INST TECHNOLOGY ; PENN STATE RES FOUND) 23 July 1998 (1998-07-23) page 39, line 26 - page 40, line 6 example 5	14-18, 20-22, 27-29
X	WO 00 28979 A (SKYEPHARMA AG) 25 May 2000 (2000-05-25) page 15, line 30 - line 32 examples 1-6	14-20, 23, 25, 27-29
X	WO 00 33789 A (R P SCHERER INC) 15 June 2000 (2000-06-15) page 4, line 4 - line 7 page 6, line 7 - line 10 examples	14-20, 25, 27-29
X	WO 00 33811 A (VECTURA LTD) 15 June 2000 (2000-06-15) example 5	14-18, 27-29

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No
PCT/GB 01/02860

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
WO 9623485	A	08-08-1996	AU 699131 B2	26-11-1998
			AU 4545696 A	21-08-1996
			BG 101858 A	30-04-1998
			BR 9607490 A	23-12-1997
			CA 2211874 A1	08-08-1996
			CZ 9702443 A3	14-01-1998
			EE 9700176 A	16-02-1998
			EP 0806938 A1	19-11-1997
			FI 973151 A	30-09-1997
			WO 9623485 A1	08-08-1996
			HU 9802209 A2	01-02-1999
			JP 10513174 T	15-12-1998
			NO 973502 A	30-09-1997
			NZ 300654 A	25-02-1999
			PL 321572 A1	08-12-1997
			SK 103697 A3	14-01-1998
			TR 9700722 T1	21-02-1998
			US 6153224 A	28-11-2000
			ZA 9600721 A	19-08-1996
EP 0260241	A	16-03-1988	AU 603139 B2	08-11-1990
			AU 7913387 A	07-04-1988
			CA 1256798 A1	04-07-1989
			DE 282537 T1	05-01-1989
			DK 247388 A	06-05-1988
			EP 0260241 A1	16-03-1988
			EP 0282537 A1	21-09-1988
			FI 882221 A	11-05-1988
			HU 47840 A2	28-04-1989
			IE 245387 L	12-03-1988
			JP 1500668 T	09-03-1989
			NO 882077 A	11-05-1988
			NZ 221732 A	28-08-1990
			WO 8801862 A1	24-03-1988
			ZA 8706641 A	14-03-1988
WO 8705213	A	11-09-1987	IT 1204826 B	10-03-1989
			AT 94755 T	15-10-1993
			AU 597964 B2	14-06-1990
			AU 7164587 A	28-09-1987
			CA 1297012 A1	10-03-1992
			DE 3787502 D1	28-10-1993
			DE 3787502 T2	20-01-1994
			DE 258356 T1	01-09-1988
			WO 8705213 A1	11-09-1987
			EP 0239798 A1	07-10-1987
			EP 0258356 A1	09-03-1988
			ES 2031839 T3	01-01-1993
			FI 874710 A ,B,	26-10-1987
			GR 88300017 T1	18-10-1988
			GR 3000879 T3	15-11-1991
			HU 46533 A2	28-11-1988
			HU 202748 B	29-04-1991
			JP 63502895 T	27-10-1988
			NO 874590 A	30-12-1987
			NZ 219484 A	27-10-1989
			ZA 8701523 A	24-08-1987

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No
PCT/GB 01/02860

Patent document cited in search report		Publication date		Patent family member(s)	Publication date
WO 9831346	A	23-07-1998	US	5855913 A	05-01-1999
			EP	0954282 A1	10-11-1999
			WO	9831346 A1	23-07-1998
			US	RE37053 E	13-02-2001
			US	5985309 A	16-11-1999
WO 0028979	A	25-05-2000	AU	6457899 A	05-06-2000
			WO	0028979 A1	25-05-2000
			EP	1131059 A1	12-09-2001
			NO	20012346 A	26-06-2001
WO 0033789	A	15-06-2000	AU	2038300 A	26-06-2000
			WO	0033789 A2	15-06-2000
WO 0033811	A	15-06-2000	AU	1577700 A	26-06-2000
			BR	9916102 A	04-09-2001
			EP	1137399 A2	04-10-2001
			WO	0033811 A2	15-06-2000
			NO	20012825 A	08-06-2001